2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $42M | $83M | $119M | $62M | $109M |
Cost of Revenue | $23M | $25M | $25M | -$76M | $0 |
Gross Profit | $19M | $59M | $95M | $137M | $109M |
Gross Profit % | 45% | 70% | 79% | 223% | 100% |
R&D Expenses | $0.35 | $1.1 | -$0.27 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $35M | $77M | -$20M | -$40M | $0 |
Dep. & Amort. | -$2.1M | -$4.6M | -$8.4M | $0 | -$2.8M |
Def. Tax | $0 | $0 | $0 | $0 | $0 |
Stock Comp. | $0 | $0 | $0 | $0 | $0 |
Chg. in WC | $4.1M | $7.7M | $1.1M | -$3.5M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $38M | $51M | $51M | $153M | $46M |
ST Investments | $0 | $0 | $949M | $0 | $0 |
Cash & ST Inv. | $38M | $51M | $1B | $153M | $46M |
Receivables | $0 | $0 | $0 | $0 | $0 |
Inventory | $0 | $0 | $0 | $0 | $0 |
TPVG reported net investment income of $12.6 million or $0.32 per share for Q4 2024, exceeding its regular quarterly dividend.
The company signed $323 million in term sheets during Q4, a 246% increase from Q3, marking the highest level in 2.5 years, with expectations for continued growth in 2025.
Portfolio yield for Q4 was 15.8%, slightly up from Q3, with total investment income for 2024 at $109 million and a portfolio yield of 15.7%.
TPVG plans to grow its portfolio in 2025, leveraging $374 million in liquidity and targeting quarterly gross investment fundings of $25-$50 million, with potential increases as market conditions improve.
The company remains focused on portfolio diversification, sector rotation into high-growth areas like AI and health tech, and maintaining credit stability, with no new additions to its watch list in Q4.